Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 14/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095845 | 0.99 | SCD (0.57) | SCDKDM4ELMNASMN1; SMN2DCTPP1 | |
| SCHEMBL1098036 | 0.97 | SCD (0.56) | SCDKDM4ELMNASMN1; SMN2DCTPP1 | |
| SCHEMBL1601644 | 0.89 | SCD (0.63) | SCDKDM4ELMNASMN1; SMN2DCTPP1 | |
| SCHEMBL1094922 | 0.87 | MEN1 (0.52) | SCDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1095707 | 0.86 | LMNA (0.44) | SCDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1094544 | 0.85 | LMNA (0.44) | SCDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1095120 | 0.84 | SCD (0.59) | SCDKDM4ELMNASMN1; SMN2DCTPP1 | |
| SCHEMBL1094940 | 0.83 | SCD (0.59) | SCDKDM4ELMNASMN1; SMN2DCTPP1 | |
| SCHEMBL1096539 | 0.83 | SCD (0.66) | SCDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1600483 | 0.83 | SCD (0.61) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | disclosed |
| US-7919484-B2 | Combination therapy | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | PYCR1, PNPO, UQCRC1 | SCD 6/4885KDM4E 3073/4885LMNA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.